0001193125-12-043917.txt : 20120207
0001193125-12-043917.hdr.sgml : 20120207
20120207170055
ACCESSION NUMBER: 0001193125-12-043917
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20111231
FILED AS OF DATE: 20120207
DATE AS OF CHANGE: 20120207
EFFECTIVENESS DATE: 20120207
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BB BIOTECH AG
CENTRAL INDEX KEY: 0000924223
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-06964
FILM NUMBER: 12578577
BUSINESS ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
BUSINESS PHONE: 411724 59 59
MAIL ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
13F-HR
1
d296131d13fhr.txt
FORM 13F-HR
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for Calendar Year or Quarter Ended: December 31, 2011
Check here if Amendment [ ]; Amendment Number:
This Amendment (Check only one.): [ ] is a restatement.
[ ] adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: BB Biotech AG
Address: Vordergasse 3
Schaffhausen Switzerland CH-8200
Form 13F File Number: 28-6964
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Pascal Schmucki
Title: SIGNING AUTHORITY
------------------
Phone: 41 (44) 267 67 00
Signature, Place, and Date of Signing: /s/ Pascal Schmucki
--------------------------------------
Schaffhausen, Switzerland,
January 31, 2012
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[_] 13F NOTICE. (Check here if no holdings reported are in this report, and
all holdings are reported by other reporting manager(s).)
[_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported
by other reporting manager(s).)
================================================================================
FORM 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 3
Form 13F Information Table Entry Total: 20
Form 13F Information Table Value Total: $ 889,002
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
No. Form 13F File Number Name
1 28-11193 Biotech Focus N.V.
2 28-11191 Biotech Invest N.V.
3 28-11189 Biotech Target N.V.
2
BB BIOTECH AG
FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
-------- -------- --------- -------- ------------------ ---------- -------- ---------------------
TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER CLASS CUSIP (X$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
-------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ----
Achillion Pharmaceuticals Inc COM 00448Q201 16,035 2,104,340 SH DEFINED 3 2,104,340 NONE NONE
Alexion Pharmaceuticals Inc COM 015351109 32,175 450,000 SH DEFINED 2 450,000 NONE NONE
Amylin Pharmaceuticals Inc COM 032346108 27,177 2,388,139 SH DEFINED 2 2,388,139 NONE NONE
Ariad Pharmaceuticals Inc COM 04033A100 39,818 3,250,448 SH DEFINED 3 3,250,448 NONE NONE
Biomarin Pharmaceutical Inc COM 09061G101 33,539 975,545 SH DEFINED 2 975,545 NONE NONE
Celgene Corp COM 151020104 189,280 2,800,000 SH DEFINED 2 2,800,000 NONE NONE
Dendreon Corp COM 24823Q107 11,586 1,524,500 SH DEFINED 2 1,524,500 NONE NONE
Endocyte Inc COM 29269A102 2,641 702,321 SH DEFINED 3 702,321 NONE NONE
Gilead Sciences Inc COM 375558103 80,223 1,960,000 SH DEFINED 1 1,960,000 NONE NONE
Halozyme Therapeutics Inc COM 40637H109 45,648 4,800,000 SH DEFINED 3 4,800,000 NONE NONE
Human Genome Sciences Inc COM 444903108 14,780 2,000,000 SH DEFINED 2 2,000,000 NONE NONE
Idenix Pharmaceuticals Inc COM 45166R204 18,481 2,482,308 SH DEFINED 3 2,482,308 NONE NONE
Immunogen Inc COM 45253H101 46,320 4,000,000 SH DEFINED 3 4,000,000 NONE NONE
Incyte Corp COM 45337C102 76,026 5,065,000 SH DEFINED 3 5,065,000 NONE NONE
Isis Pharmaceuticals Inc COM 464330109 52,156 7,233,800 SH DEFINED 3 7,233,800 NONE NONE
Micromet Inc COM 59509C105 48,039 6,681,397 SH DEFINED 3 6,681,397 NONE NONE
Optimer Pharmaceuticals Inc COM 68401H104 17,659 1,442,700 SH DEFINED 3 1,442,700 NONE NONE
Pharmasset Inc COM 71715N106 19,230 150,000 SH DEFINED 3 150,000 NONE NONE
Theravance Inc COM 88338T104 18,636 843,244 SH DEFINED 3 843,244 NONE NONE
Vertex Pharmaceuticals Inc COM 92532F100 99,553 2,997,684 SH DEFINED 3 2,997,684 NONE NONE
3